ArticleJournal of clinical immunology2026
Characteristics of Mycobacterial, COVID-19, and Talaromyces Marneffei Infections in Patients with IL12RB1 and IFNGR1 Mutations in Western China.
Article in Journal of clinical immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundMendelian susceptibility to mycobacterial disease (MSMD) is a rare immunodeficiency characterized by increased vulnerability to weakly virulent mycobacteria. However, its clinical and molecular spectrum, as well as its susceptibility to infections beyond mycobacteria, remains incompletely understood.
objectiveTo evaluate the clinical and genetic characteristics of MSMD patients, focusing on their susceptibility to mycobacteria, SARS-CoV-2 and endemic fungal infections.
methodsThirteen MSMD patients underwent genetic analyses, immunological assays, and clinical evaluations. COVID-19 outcomes were documented. Pathological findings and mNGS confirmed Talaromyces marneffei infections.
resultsFollowing BCG vaccination, 92.3% (12/13) developed regional or disseminated infections. Additional infections included severe tuberculosis and Mycobacterium avium. All patients experienced SARS-CoV-2 infections and present mild symptoms. One IL12RB1-deficient patient presented with isolated disseminated Talaromyces marneffei infection but otherwise healthy. Another AR IFNGR1-deficient patient with concurrent mycobacterial and fungal infections. Genetic analysis identified five novel mutations (c.155G > C, p.C52S, c. 617 A > C, p.Q206P, c.923 A > G; p.Y308C, c.1282_1301deIACCTTGTGGTCTACGGTCCTinsC; p.T428fs* in IL12RB1 and c.811 A > T, p.K271X in IFNGR1). Functional assays confirmed impaired IL12-IFNγ axis signaling. Patients with partial IFNGR1 defects showed complete clinical remission with higher doses IFN-γ therapy basing on STAT1 phosphorylation dynamics analysis under IFN-γ activation in vitro.
conclusionThe patient experienced significant diagnostic delays. Adverse reactions to BCG vaccination, NTM infection or severe mycobacteria tuberculosis infections in other wise healthy children strongly suggest MSMD. MSMD patients are susceptible to SARS-CoV-2 but do not exhibit severe COVID-19. Talaromyces marneffei could be an initial manifestation of MSMD in endemic regions. Early diagnosis and targeted therapy, including IFNγ and anti-tuberculosis treatments, are critical to improving outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.